성인 악성 교종 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global adult malignant glioma therapeutics market size is expected to reach USD 8.16 Billion in 2034 from USD 3.23 Billion in 2025, growing at a CAGR of 10.86% during 2026-2034.This market is witnessing significant growth driven by the increasing incidence of malignant gliomas and the need for effective treatment options. Malignant gliomas are aggressive brain tumors that require advanced therapeutic approaches, including surgery, radiation, and chemotherapy. The growing focus on oncology research and the development of targeted therapies are significantly contributing to market expansion.

Key drivers include rising investments in cancer research, advancements in treatment technologies, and increasing awareness about brain tumors. Pharmaceutical companies are focusing on developing innovative therapies, including immunotherapy and gene therapy, to improve patient outcomes. The expansion of clinical trials and collaborations between research institutions and biotech companies are also supporting market growth.

Future prospects for this market remain promising, with continuous innovation in personalized medicine and targeted therapies. The integration of advanced diagnostic tools and treatment planning systems will enhance treatment effectiveness. Emerging markets are expected to offer significant growth opportunities due to improving healthcare access. As research continues to advance, the adult malignant glioma therapeutics market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy

• Chemotherapy
• Radiotherapy
• Targeted therapy
• Others

By Disease

• Glioblastoma Multiforme
• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Others

By End User

• Hospitals
• Specialty Clinics
• Cancer and Radiation Therapy Centers
• Others

COMPANIES PROFILED

• Merck & Co., Roche, Novartis, Bristol Myers Squibb, AstraZeneca, Eli Lilly, Pfizer, AbbVie, Daiichi Sankyo, Servier, Denovo Biopharma, Kazia Therapeutics, VBI Vaccines, AnHeart Therapeutics, Tocagen, Northwest Biotherapeutics, Celldex Therapeutics, Imvax, CNS Pharmaceuticals, GT Medical Technologies

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ADULT MALIGNANT GLIOMA THERAPEUTICS MARKET: BY THERAPY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy
• 4.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Radiotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Targeted therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ADULT MALIGNANT GLIOMA THERAPEUTICS MARKET: BY DISEASE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease
• 5.2. Glioblastoma Multiforme Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Anaplastic Astrocytoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Anaplastic Oligodendroglioma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ADULT MALIGNANT GLIOMA THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cancer and Radiation Therapy Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ADULT MALIGNANT GLIOMA THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy
  • 7.2.2 By Disease
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy
  • 7.3.2 By Disease
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy
  • 7.4.2 By Disease
  • 7.4.3 By End User
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy
  • 7.5.2 By Disease
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy
  • 7.6.2 By Disease
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ADULT MALIGNANT GLIOMA THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Merck & Co
  • 9.2.2 Roche
  • 9.2.3 Novartis
  • 9.2.4 Bristol Myers Squibb
  • 9.2.5 AstraZeneca
  • 9.2.6 Eli Lilly
  • 9.2.7 Pfizer
  • 9.2.8 AbbVie
  • 9.2.9 Daiichi Sankyo
  • 9.2.10 Servier
  • 9.2.11 Denovo Biopharma
  • 9.2.12 Kazia Therapeutics
  • 9.2.13 VBI Vaccines
  • 9.2.14 AnHeart Therapeutics
  • 9.2.15 Tocagen
  • 9.2.16 Northwest Biotherapeutics
  • 9.2.17 Celldex Therapeutics
  • 9.2.18 Imvax
  • 9.2.19 CNS Pharmaceuticals
  • 9.2.20 GT Medical Technologies